VISION Trial Videos - Results from #20

VISION Trial Videos

Search

177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris Details In a plenary presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Michael Morris, MD, presented awaited results of the Phase III VISION trial. The study is evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard o...
The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care - Re-envisioning the Future - Zachary Klaassen and Christopher J.D. Wallis Details Recorded Date: September 8, 2020 The coronavirus disease 2019 (COVID-19) (SARS-CoV-2) pandemic necessitated rapid changes in medical practice. Many of these changes may add value to care, creating opportunities going forward. In this journal club, Zachary Klaassen, MD, MSc, and Christorpher Wallis, MD, PhD, discuss the impacts of the COVID-19 pandemic on genitourinary cancer care, and how we can r...
PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Pivotal Phase III VISION Trial - Oliver Sartor Details PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer. Module 5 12 minutes: PSMA Targeted Radiopharmaceuticals in Prostate Cancer: Introducing the Pivotal Phase III VISION Trial - Presented by Oliver Sartor, MD 11 minutes: Discussion Moderators Phillip J. Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS Biographies: Oliver Sartor, M.D. C.E. and Bernadine Laborde Professor of...
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris Details At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Oliver Sartor and Michael Morris join Charles to discuss lutetium in advanced prostate cancer and the VISION trial. Dr. Michael Morris serves on the scientific oversight committee of the trial, and Dr. Sartor is one of the co-PIs of this clinical trial. The VISION trial has the potential to change clinical practice in the...
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor Details Oliver Sartor joins Charles Ryan to talk about the VISION trial, a trial testing the PSMA-617 agent, The novel therapeutic drug 177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective of this study is to compare the 2 alternative en...